• SELECT SITE CURRENCY
Select a currency for use throughout the site
France Pharmaceuticals and Healthcare Report Q3 2008
Business Monitor International, September 2008, Pages: 74
Our France Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on France's pharmaceuticals and healthcare industry.
The French pharmaceutical market is one of the most advanced in the world but has been experiencing solid growth in recent years. The author expects this to continue over the forecast period – despite government efforts at cost containment – which is a testament to the country’s continuing high consumption levels.
Up to 2012, nominal growth should be around the 3.5% per year, comfortably outpacing inflation. France is also the largest drug producer in Western Europe and a hub for R&D research, although both of these attributes are threatened by a growing trend towards outsourcing.
The biggest change this quarter has been the continuing liberalisation of the OTC sector. Regulatory changes are to allow some 200 non-prescription drugs to be sold in front of the counter, despite complaints from pharmacies that this could cause stiff price competition. The authorities are still resisting calls to allow the sales of self-medication products in non-pharmacy outlets such as supermarkets, despite a number of high-profile campaigns.
It is understandable why the government is keen to move as much drug expenditure away from the State as possible. France's social security budget deficit widened in 2007 to EUR9.5bn (US$14.8bn), according to government auditors. In 2006, the deficit was EUR8.7bn (US$13.6bn), and the social security auditors (CCS) have identified a 4.2% increase in pharmaceutical expenditure, which contributed EUR2bn (US$3.1bn) to the overall deficit. In spite of this increase in pharmaceutical spending, there was actually a 28% reduction in the healthcare deficit in 2007, to EUR4.6bn (US$7.2bn), largely owing to health charges and increased tax revenues.
Meanwhile, France remains in third place in our Business Environment Ranking For Western Europe, trailing Switzerland and Germany but ahead of the UK. As the market continues to develop the author would not be surprised if France moved up to second place in coming quarters, as growth by regional terms remains robust.
France Pharmaceuticals And Healthcare Industry SWOT
France Political SWOT
France Economic SWOT
Pharmaceutical Business Environment Ratings
Risks To Realisation Of Returns
Table: Western Europe Pharmaceutical Business Environment Rankings
France – Market Summary
Intellectual Property Developments
Pricing And Reimbursement Issues
FRANCE REIMBURSEMENT CATEGORIES
Public Health Issues
Research And Development Sector
Table: New French Taxes On Private-Sector Research Applications
Table: First Parallel Imports In France
Industry Forecast Scenario
Overall Market Forecast
Table: France Drug Market Expenditure Forecast Indicators
Key Factors – Industry
Table: France’s Health Expenditure Indicators, 2005-2012 45
Key Growth Factors – Macroeconomic
Table: France - Macroeconomic Forecasts
Patented Market Forecast
Table: France Patented Drugs Market Forecast Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: France OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecasts
Table: France’s Generics Market Indicators
Table: Sectoral Trade Indicators (US$mn)
Other Healthcare Data And Forecasts
Table: Socio-Demographic Indicators
Key Risks To Our Forecasts
Leading Multinational Manufacturers
Merck & Co
Major Indigenous Companies
Our Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components
- GlaxoSmithKline (GSK)
- Merck & Co
A sample for this product is available. Please Login/Register to download this sample.